ACRV

insider transactions

Acrivon Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Other·F
May 21, 26

Peter Blume-Jensen / Kristina Masson KEY

President and CEO

$24.6K

13.7K sh · $1.79

Own -1%
Grant·A
May 18, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$0

9.4K sh

Own New
Grant·A
May 18, 26

Michael John Tomsicek

Director

$0

9.4K sh

Own New
Grant·A
May 18, 26

Sharon Shacham

Director

$0

9.4K sh

Own New
Grant·A
May 18, 26

Santhosh Palani

Director

$0

9.4K sh

Own New
Grant·A
May 18, 26

Ivana Magovcevic-Liebisch

Director

$0

9.4K sh

Own New
Grant·A
May 18, 26

Derek Dirocco

Director

$0

9.4K sh

Own New
Grant·A
May 18, 26

Charles M Baum

Director

$0

9.4K sh

Own New
Grant·A
May 18, 26

Katharine Peterson

Chief Accounting Officer

$0

14.2K sh

Own +364%
Grant·A
May 18, 26

Mansoor Raza Mirza

Chief Medical Officer

$0

38.8K sh

Own New
Grant·A
May 18, 26

Mary Miller

Chief Legal Officer

$0

49.8K sh

Own +151%
Grant·A
May 18, 26

Adam D. Levy KEY

Chief Financial Officer

$0

46.2K sh

Own +220%
Grant·A
May 18, 26

Erick Gamelin

Chief Development Officer

$0

38.6K sh

Own +268%
Grant·A
May 18, 26

Eric Devroe

Chief Operating Officer

$0

73.0K sh

Own +99%
Grant·A
May 18, 26

Peter Blume-Jensen / Kristina Masson KEY

President and CEO

$0

72.7K sh

Own +23%
Grant·A
May 18, 26

Peter Blume-Jensen / Kristina Masson KEY

President and CEO

$0

180.1K sh

Own +9%
Other·F
May 14, 26

Katharine Peterson

Chief Accounting Officer

$190

99 sh · $1.92

Own -2%
Other·F
May 14, 26

Mary Miller

Chief Legal Officer

$353

184 sh · $1.92

Own -1%
Other·F
May 14, 26

Erick Gamelin

Chief Development Officer

$776

404 sh · $1.92

Own -3%
Other·F
May 14, 26

Eric Devroe

Chief Operating Officer

$1.2K

613 sh · $1.92

Own -1%
Other·F
May 14, 26

Peter Blume-Jensen / Kristina Masson KEY

President and CEO

$941

490 sh · $1.92

Own -0%
Other·F
May 14, 26

Peter Blume-Jensen / Kristina Masson KEY

President and CEO

$2.4K

1.3K sh · $1.92

Own -0%
Grant·A
Apr 22, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$7.0M

3.9M sh · $1.80

Own +49%
Other·F
Apr 17, 26

Mary Miller

Chief Legal Officer

$993

558 sh · $1.78

Own -2%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 21, 2026	Peter Blume-Jensen / Kristina Masson KEY	President and CEO	Other F	13.7K	-1%	$1.79	$24.6K
May 18, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Grant A	9.4K	New	—	$0
May 18, 2026	Michael John Tomsicek	Director	Grant A	9.4K	New	—	$0
May 18, 2026	Sharon Shacham	Director	Grant A	9.4K	New	—	$0
May 18, 2026	Santhosh Palani	Director	Grant A	9.4K	New	—	$0
May 18, 2026	Ivana Magovcevic-Liebisch	Director	Grant A	9.4K	New	—	$0
May 18, 2026	Derek Dirocco	Director	Grant A	9.4K	New	—	$0
May 18, 2026	Charles M Baum	Director	Grant A	9.4K	New	—	$0
May 18, 2026	Katharine Peterson	Chief Accounting Officer	Grant A	14.2K	+364%	—	$0
May 18, 2026	Mansoor Raza Mirza	Chief Medical Officer	Grant A	38.8K	New	—	$0
May 18, 2026	Mary Miller	Chief Legal Officer	Grant A	49.8K	+151%	—	$0
May 18, 2026	Adam D. Levy KEY	Chief Financial Officer	Grant A	46.2K	+220%	—	$0
May 18, 2026	Erick Gamelin	Chief Development Officer	Grant A	38.6K	+268%	—	$0
May 18, 2026	Eric Devroe	Chief Operating Officer	Grant A	73.0K	+99%	—	$0
May 18, 2026	Peter Blume-Jensen / Kristina Masson KEY	President and CEO	Grant A	72.7K	+23%	—	$0
May 18, 2026	Peter Blume-Jensen / Kristina Masson KEY	President and CEO	Grant A	180.1K	+9%	—	$0
May 14, 2026	Katharine Peterson	Chief Accounting Officer	Other F	99	-2%	$1.92	$190
May 14, 2026	Mary Miller	Chief Legal Officer	Other F	184	-1%	$1.92	$353
May 14, 2026	Erick Gamelin	Chief Development Officer	Other F	404	-3%	$1.92	$776
May 14, 2026	Eric Devroe	Chief Operating Officer	Other F	613	-1%	$1.92	$1.2K
May 14, 2026	Peter Blume-Jensen / Kristina Masson KEY	President and CEO	Other F	490	-0%	$1.92	$941
May 14, 2026	Peter Blume-Jensen / Kristina Masson KEY	President and CEO	Other F	1.3K	-0%	$1.92	$2.4K
Apr 22, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Grant A	3.9M	+49%	$1.80	$7.0M
Apr 17, 2026	Mary Miller	Chief Legal Officer	Other F	558	-2%	$1.78	$993

About ACRV insider trading

This page tracks insider transactions for Acrivon Therapeutics, Inc. (ACRV) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.